Henry Schein (HSIC) sets the stage with steady top line and consistent earnings

Henry Schein (HSIC) opened Q1 2026 earnings season on the back of Q4 2025 revenue of about $3.4 billion and basic EPS of $0.86, with trailing twelve month figures at $13.2 billion of revenue and EPS of $3.29 helping frame the latest print. Over the past year, revenue has moved from $12.7 billion to $13.2 billion while trailing EPS shifted from $3.08 to $3.29, giving you a clearer sense of how the top line and per share earnings have tracked into this quarter. With a 3% trailing net margin that is slightly below last year’s 3.1%, the story this season is about how much of that revenue the company is converting into profit.

See our full analysis for Henry Schein.

With the numbers on the table, the next step is to see how they line up with the widely discussed narratives around Henry Schein’s growth, profitability and risk profile, and where those stories may need updating.

Margins stuck around the 3% mark

• Trailing twelve month net income is US$398 million on US$13.2b of revenue, which works out to a 3% net margin compared with 3.1% a year ago.
• Consensus narrative points to margin expansion, yet current figures still sit at 3%, so the idea of higher future margins rests heavily on planned cost savings and mix shift rather than anything already visible in reported profitability.
  • Analysts are talking about profit margins moving toward 3.8% over the next few years, but the last year shows only a slight margin compression in the reported numbers.
  • Value creation initiatives and more high margin segments could help, however so far net income has hovered near US$390 million to US$407 million on roughly US$12.5b to US$13.2b of revenue.

Earnings trend improves from a weak five year run

• Five year earnings have declined by about 12.3% per year on average, while the most recent annual move was 2.3% earnings growth, which is a clear break from that longer run rate.
• Bulls argue that focus on high margin segments and digital tools will support steadier growth, and the recent 2.3% earnings increase versus the longer 12.3% annual decline is one concrete data point they highlight.
  • Trailing EPS has moved from US$2.45 in Q3 2024 to US$3.29 by Q4 2025, which lines up with the idea that recent profitability is firmer than the five year average would suggest.
  • At the same time, the five year decline figure keeps the cautious view alive, because it shows the business has not had a straight line earnings path into this latest period.

Bulls say this recent EPS recovery could be the early stages of a longer earnings rebuild, while others see it as only a short pause in a tougher five year trend, so it is worth seeing how that debate is framed in the detailed bullish case for Henry Schein. 🐂 Henry Schein Bull Case

P/E discount and DCF gap stand out

• The stock trades on a 21.4x P/E versus about 24.9x for the US Healthcare industry and 25.8x for peers, and the current share price of US$74.37 sits well below a DCF fair value of about US$166.36.
• Bears highlight that a low margin of 3% and a weak five year earnings record can justify some discount, even if the current P/E and the DCF fair value gap suggest the market is already pricing in a lot of caution.
  • The roughly 3.5 to 4.5 turn P/E discount against industry and peers exists alongside that 3% net margin, which is thin compared with many healthcare distributors and gives skeptics a clear point to focus on.
  • Five year earnings contraction of about 12.3% per year provides more support for a discounted multiple, because it shows that the business has had to work through a period of weaker profitability before the most recent 2.3% growth.

Critics argue that thin margins and that five year earnings decline help explain why the market is unwilling to match either peer P/E levels or the high DCF fair value, so it can be useful to see how those risks are laid out in the more cautious take on Henry Schein. 🐻 Henry Schein Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Henry Schein on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both risks and rewards in this story. Now is a good time to review the numbers yourself, weigh the trade offs, and check the 3 key rewards and 2 important warning signs.

See What Else Is Out There

Henry Schein’s thin 3% net margin and a five year trend of about 12.3% annual earnings decline highlight pressure on profitability and consistency.

If that mix of tight margins and uneven earnings leaves you uneasy, it is worth lining up alternatives with stronger profit resilience using the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.